Fucosyltransferase Engineered E. coli for HMOS Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of human milk oligosaccharides (HMOS) is hindered by high costs, stereo-specificity issues, and limited availability of precursor molecules, making it challenging to manufacture large quantities inexpensively through chemical synthesis or existing methods.
Innovation Solution
A nucleic acid construct encoding a lactose-utilizing α(1,2)fucosyltransferase enzyme, specifically the FutL enzyme, is used to produce fucosylated oligosaccharides in bacteria like E. coli, enhancing intracellular pools of lactose and GDP-fucose, and reducing β-galactosidase activity to efficiently synthesize HMOS like 2'-fucosyllactose and lactodifucotetraose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemical synthesis is used to produce human milk oligosaccharides, then production capability is achieved, but cost is high and stereo-specificity issues occur
Solution Approach 1:
The patent replaces chemical synthesis methods with a biological system (genetically engineered bacteria) to produce human milk oligosaccharides. The bacteria express fucosyltransferase enzymes that catalyze the formation of fucosylated oligosaccharides through biochemical pathways, substituting chemical reactions with enzymatic processes that naturally occur in living systems.
Solution Approach 2:
The genetically engineered bacteria serve themselves by utilizing their own metabolic pathways and intracellular pools of precursors (GDP-fucose and lactose) to synthesize the desired oligosaccharides. The bacteria's natural cellular machinery, including its enzyme systems and metabolic networks, is harnessed to produce the target compounds without requiring external chemical synthesis infrastructure.
2Productivity
If existing methods are used to produce HMOS, then some production is achieved, but precursor availability is limited and costs remain high
Solution Approach 1:
The patent enhances the intracellular pools of precursors (GDP-fucose and lactose) within the bacterial cells before the actual oligosaccharide synthesis occurs. By pre-accumulating these essential building blocks through metabolic engineering and optimized culture conditions, the system ensures sufficient substrate availability for high-level product formation.
Solution Approach 2:
The bacterial host system performs multiple functions: it serves as a factory for synthesizing GDP-fucose through its metabolic pathways, stores lactose as an intracellular precursor, expresses the fucosyltransferase enzyme, and ultimately produces the fucosylated oligosaccharides. This multi-functional biological system replaces the need for separate precursor synthesis and assembly steps required in chemical methods.
3Productivity
If β-galactosidase activity is present in the production system, then lactose metabolism occurs, but oligosaccharide production efficiency decreases
Solution Approach 1:
The patent removes or reduces β-galactosidase activity from the bacterial production system. By eliminating this enzyme that would otherwise metabolize lactose, the system prevents the degradation of the lactose precursor and directs metabolic flux toward oligosaccharide synthesis instead, thereby improving production efficiency.
4Quantity of substance
If recombinant fucosyltransferase is produced in bacteria, then enzyme availability increases, but enzyme stability and toxicity issues arise
Solution Approach 1:
The patent optimizes various parameters including the bacterial host strain selection, cultivation conditions, and enzyme expression levels to enhance the stability and safety of the recombinant fucosyltransferase. By adjusting these parameters, the system achieves high enzyme availability while maintaining cellular viability and product safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the economical and efficient production of high-purity fucosylated oligosaccharides, such as 2'-fucosyllactose, overcoming previous limitations by using genetically engineered bacteria to achieve commercially viable yields and improved stability of the enzyme, reducing toxicity, and ensuring safety for use in dietary supplements.
Implementation Method 1
a nucleic acid encoding a lactose- utilizing α(1,2)fucosyltransferase enzyme... the amino acid sequence of said enzyme encoded by said nucleic acid comprises the sequence of SEQ ID NO: 8 for producing a fucosylated oligosaccharide
Data Source
Figure 1~2
Figure 3A~3C
Figure 4
AI summary
The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.